Skip to main content
Livermore
Livermore
ZHEN

BVF Inc

SEC CIK
0001056807
Latest filing
Aug 14, 2026

The latest 13F from BVF Inc covers Q2 2026 (filed Aug 14, 2026): 44 long positions worth $3.91B. The top 10 holdings make up 65.6% of the portfolio, and the largest is Revolution Medicines, Inc. (RVMD) at 14.2%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
5
Est. +$86.3M
Added
6
Est. +$262.5M
Reduced
8
Est. −$336.5M
Sold out
2
Est. −$73.6M

Top 5 holdings

Share of this quarter's portfolio value

  1. RVMDRevolution Medicines, Inc.
    14.2%$555.3MHistory
  2. KYMRKymera Therapeutics, Inc.
    11.4%$444.0MHistory
  3. XOMAXOMA Royalty Corp
    8.3%$322.7MHistory
  4. MLTXMoonLake Immunotherapeutics
    8.0%$311.5MHistory
  5. GHRSGH Research PLC
    5.9%$232.5MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. XOMAXOMA Royalty Corp
    +$212.6MAddedHistory
  2. QTTBQ32 Bio Inc.
    +$29.9MNewHistory
  3. ABSIAbsci Corp
    +$27.4MNewHistory
  4. RVMDRevolution Medicines, Inc.
    +$20.3MAddedHistory
  5. SGMTSagimet Biosciences Inc.
    +$19.3MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. XOMAXOMA Royalty Corp
    +5.66 pp2.6% → 8.3%History
  2. RVMDRevolution Medicines, Inc.
    +5.35 pp8.9% → 14.2%History
  3. QTTBQ32 Bio Inc.
    +0.77 pp0.0% → 0.8%History
  4. ABSIAbsci Corp
    +0.70 pp0.0% → 0.7%History
  5. ALKSAlkermes plc.
    +0.63 pp2.3% → 2.9%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. KYMRKymera Therapeutics, Inc.
    −$187.0MReducedHistory
  2. MIRMMirum Pharmaceuticals, Inc.
    −$61.9MReducedHistory
  3. PVLAPalvella Therapeutics, Inc.
    −$44.0MReducedHistory
  4. CMPXCompass Therapeutics, Inc.
    −$41.1MSold outHistory
  5. SEPNSepterna, Inc.
    −$32.5MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. KYMRKymera Therapeutics, Inc.
    −3.25 pp14.6% → 11.4%History
  2. NKTRNektar Therapeutics
    −1.60 pp5.9% → 4.3%History
  3. MIRMMirum Pharmaceuticals, Inc.
    −1.50 pp4.7% → 3.2%History
  4. CMPXCompass Therapeutics, Inc.
    −1.31 pp1.3% → 0.0%History
  5. TYRATyra Biosciences, Inc.
    −1.21 pp2.4% → 1.2%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$3.91B
+$772.0M (+24.6%) vs. prior quarter
Positions
44
+3 vs. prior quarter
Top 10 concentration
65.6%
Top 10 as share of value
Turnover
9.9%
Q2 2026, one quarter
Average holding period
15.3 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $4.00B (Q4 2023)

Q1 2021: $2.67BQ2 2021: $2.67BQ3 2021: $2.56BQ4 2021: $2.76BQ1 2022: $2.50BQ2 2022: $2.07BQ3 2022: $2.42BQ4 2022: $2.37BQ1 2023: $2.74BQ2 2023: $3.59BQ3 2023: $3.71BQ4 2023: $4.00BQ1 2024: $3.64BQ2 2024: $3.57BQ3 2024: $3.42BQ4 2024: $2.95BQ1 2025: $2.45BQ2 2025: $2.80BQ3 2025: $2.47BQ4 2025: $2.97BQ1 2026: $3.14BQ2 2026: $3.91B
Q1 2021Q2 2026
13F filings of BVF Inc by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202644$3.91BRVMDKYMRXOMAvs. Q1 2026SEC
Q1 2026May 15, 202641$3.14BKYMRMLTXRVMDvs. Q4 2025SEC
Q4 2025Feb 17, 202641$2.97BKYMRRVMDMLTXvs. Q3 2025SEC
Q3 2025Nov 14, 202546$2.47BKYMRRVMDPTGXvs. Q2 2025SEC
Q2 2025Aug 14, 202544$2.80BMLTXKYMRRVMDvs. Q1 2025SEC
Q1 2025May 15, 202551$2.45BMLTXAXSMRVMDvs. Q4 2024SEC
Q4 2024Feb 14, 202553$2.95BMLTXKYMRRVMDvs. Q3 2024SEC
Q3 2024Nov 14, 202455$3.42BMLTXKYMRRVMDvs. Q2 2024SEC
Q2 2024Aug 14, 202460$3.57BMLTXRVMDKYMRvs. Q1 2024SEC
Q1 2024May 15, 202462$3.64BMLTXKYMRRVMDvs. Q4 2023SEC
Q4 2023Feb 14, 202470$4.00BMLTXRVMDAXSMvs. Q3 2023SEC
Q3 2023Nov 14, 202369$3.71BMLTXIONSAXSMvs. Q2 2023SEC
Q2 2023Aug 14, 202367$3.59BMLTXRVMDAXSMvs. Q1 2023SEC
Q1 2023May 15, 202372$2.74BMLTXKYMRAXSMvs. Q4 2022SEC
Q4 2022Feb 14, 202378$2.37BMLTXAXSMRPTXvs. Q3 2022SEC
Q3 2022Nov 14, 202280$2.42BMLTXIONSGHRSvs. Q2 2022SEC
Q2 2022Aug 15, 202279$2.07BRPTXMLTXRCUSvs. Q1 2022SEC
Q1 2022May 16, 202281$2.50BGHRSKYMRRLAYvs. Q4 2021SEC
Q4 2021Feb 14, 202283$2.76BGHRSKYMRRCUSvs. Q3 2021SEC
Q3 2021Nov 15, 202175$2.56BGHRSKYMROLMAvs. Q2 2021SEC
Q2 2021Aug 16, 202170$2.67BGHRSARGXOLMAvs. Q1 2021SEC
Q1 2021May 17, 202167$2.67BFive Prime Therapeutics IncOLMAMRUS–SEC

13D and 13G filings

Companies where BVF Inc reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

BVF Inc does not currently report owning 5% or more of any company.

Latest filings

121 filings on file made by BVF Inc or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by BVF Inc
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
TYRATyra Biosciences, Inc.Sep 21, 20265:21 PM ETBiotechnology Value Fund L Pand 9 others13G6.10%4.22M shares+2.10 ppfrom 4.00%Sep 14, 2026SEC
ALECAlector, Inc.Sep 18, 20264:57 PM ETBiotechnology Value Fund L Pand 9 others13G8.40%9.37M sharesNewSep 11, 2026SEC
TENXTenax Therapeutics, Inc.Aug 14, 20264:22 PM ETBiotechnology Value Fund L Pand 9 others13G/A9.99%3.11M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
TCRXTScan Therapeutics, Inc.Aug 14, 20264:19 PM ETBiotechnology Value Fund L Pand 9 others13G/A9.99%6.42M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
PVLAPalvella Therapeutics, Inc.Aug 14, 20264:18 PM ETBiotechnology Value Fund L Pand 9 others13G/A4.70%672.8K shares−2.40 ppfrom 7.10%Below 5%Jun 30, 2026SEC
OKUROnKure Therapeutics, Inc.Aug 14, 20264:15 PM ETBiotechnology Value Fund L Pand 9 others13G/A8.00%3.24M shares+2.70 ppfrom 5.30%Jun 30, 2026SEC
NKTRNektar TherapeuticsAug 14, 20264:13 PM ETBiotechnology Value Fund L Pand 9 others13G/A7.10%2.39M shares−2.70 ppfrom 9.80%Jun 30, 2026SEC
IVVDInvivyd, Inc.Aug 14, 20264:10 PM ETBiotechnology Value Fund L Pand 9 others13G/A9.99%29.6M shares+0.99 ppfrom 9.00%Jun 30, 2026SEC
IMAImageneBio, Inc.Aug 14, 20264:08 PM ETBiotechnology Value Fund L Pand 9 others13G/A9.90%1.13M shares0.00 ppfrom 9.90%Jun 30, 2026SEC
CGEMCullinan Therapeutics, Inc.Aug 14, 20264:06 PM ETBiotechnology Value Fund L Pand 9 others13G/A9.99%6.49M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
AVTXAvalo Therapeutics, Inc.Aug 14, 20264:01 PM ETBiotechnology Value Fund L Pand 9 others13G/A5.30%2.80M shares−4.69 ppfrom 9.99%Jun 30, 2026SEC
TCGXTCGX Acquisition Corp.Aug 12, 20264:55 PM ETBiotechnology Value Fund L Pand 9 others13G5.50%500.0K sharesNewAug 5, 2026SEC
ENTXEntera Bio Ltd.Aug 4, 20267:07 PM ETBiotechnology Value Fund L Pand 9 others13D9.99%17.2M sharesNewJul 28, 2026SEC
RACDResearch Alliance Corp IVJul 20, 20266:22 PM ETBiotechnology Value Fund L Pand 9 others13G6.40%500.0K sharesNewJul 13, 2026SEC
XOMAXOMA Royalty CorpJul 16, 20265:00 PM ETBiotechnology Value Fund L Pand 9 others13D/A0.00%0 shares−43.30 ppfrom 43.30%Below 5%Jul 14, 2026SEC
PYXSPyxis Oncology, Inc.Jul 10, 20264:07 PM ETBiotechnology Value Fund L Pand 9 others13G9.99%8.34M shares–Jul 2, 2026SEC
MLTXMoonLake ImmunotherapeuticsJun 29, 20265:20 PM ETBiotechnology Value Fund L Pand 10 others13D/A19.70%16.0M shares−2.60 ppfrom 22.30%Jun 25, 2026SEC
KYMRKymera Therapeutics, Inc.Jun 26, 20266:43 PM ETBiotechnology Value Fund L Pand 10 others13D/A6.30%5.24M shares−2.20 ppfrom 8.50%Jun 26, 2026SEC
QTTBQ32 Bio Inc.Jun 4, 20265:06 PM ETBiotechnology Value Fund L Pand 9 others13G9.99%2.37M sharesNewMay 28, 2026SEC
RACCResearch Alliance Corp IIIMay 29, 20265:51 PM ETBiotechnology Value Fund L Pand 9 others13G6.40%500.0K sharesNewMay 21, 2026SEC